ArticleCureus2025

Complete Response After One Cycle of Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma: Two High-Risk Contexts, Child-Pugh Class B and Advanced Age.

Masamichi Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.